Bryant Furlow

Genetic sequencing of tumors to identify targeted therapy options appears to delay tumor progression and prolong patient survival.

A simple blood draw to evaluate cfDNA might one day be used for early-stage lung cancer screening-if the mutational “noise” of normal aging can be addressed.

The addition of atezolizumab to chemotherapy was associated with superior PFS but did not improve preliminary OS.

Obese patients survived longer during immune checkpoint blockade for metastatic lung cancer compared with underweight patients and those who lost weight during treatment.

Pembrolizumab has shown activity against some lung cancer metastases in the brain, but responses can be discordant with extracranial tumor responses.

Activating oncogene mutations do not predict lung tumor responses to immune checkpoint blockade, ImmunoTarget investigators found.

No one molecular biomarker is likely to guide treatment of RCC in the foreseeable future. Multipredictor models might be a way forward, an expert concluded.

Can you name biomarkers that are associated with PCNS-DLBCL? Are you aware of contraindications for use of rituximab in DLBCL? Test your knowledge by taking this multiquestion quiz.

Challenge yourself with our latest quiz, covering management considerations in the treatment of patients with transplant-ineligible myeloma.

What are appropriate sources of stem cells for HCT in patients without an HLA-matched, related donor? Is post-transplant cyclophosphamide–based haploidentical donor transplantation appropriate for racial and ethnic minority patients with hematologic cancers? Test your knowledge with this multiquestion quiz.

Pooled data show PET imaging of metabolic tumor burden at diagnosis helps identify patients most at risk of FL recurrence.

Take our latest quiz to learn about differences in MM incidence, complications, and treatment among men, women, and various racial and ethnic groups.

Follicular large cleaved cell lymphoma is frequently misclassified, according to researchers.

At SGO 2018, an early study showed ‘encouraging’ PFS with trastuzumab added to combination carboplatin/paclitaxel for advanced HER2/neu-overexpressing uterine serous carcinoma.

An analysis presented at SGO 2018 concluded strong and consistent clinician recommendations might boost HPV vaccination rates among teens, particularly boys.

A study presented at the SGO Annual Meeting found that PARP-7 amplification mutations are associated with prolonged survival among patients with platinum-sensitive ovarian cancer.

A study presented at the SGO Annual Meeting found that elderly women have higher rates of cervical cancer than previously thought, suggesting screening guidelines should be reconsidered.

ACA Medicaid expansion benefited women younger than 65 who were diagnosed with a gynecologic cancer between 2011 and 2014, a SEER database analysis found.

An “ultra-restrictive” policy to reduce opioid prescribing to women who underwent major gynecologic cancer surgeries dramatically reduced opioid use.

Should a patient with fallopian tube cancer undergo genetic risk evaluation? What is essential in post-treatment monitoring of ovarian, fallopian tube, and primary peritoneal cancers? Take this multiquestion quiz to find out.  

Which agents are associated with increased risk of sarcomas in childhood leukemia? What are the most common secondary cancers among survivors of childhood leukemias, lymphomas, and other childhood malignancies? Take this multiquestion quiz to find out.

How much do you understand about evaluating prognosis and choosing treatment for patients with myeloma? Take our latest quiz to find out.

Umbralisib, a dual inhibitor of PI3Kδ and casein kinase-1Ɛ, was well tolerated and showed early signs of clinical activity in a phase I lymphoma study.

In a Canadian survey, lung cancer patients were more likely to report that they should be asked about their smoking status at every clinic visit.

In a study of over 100,000 adults, overall cancer risk, particularly of breast cancer, was associated with dietary intake of ultra-processed foods.

FL progression risk at 2 years was twice as high in the high-risk vs the low-risk group, and the gene-expression score may help to guide treatment.

Pazopanib was not associated with prolonged progression-free survival compared with temsirolimus among patients with advanced clear-cell renal cell carcinoma, but a subgroup analysis of intermediate-risk patients offered some reason for optimism.

Adjuvant platinum-based chemotherapy is associated with delayed metastasis among patients diagnosed with upper-tract urothelial carcinoma, according to findings from the phase III POUT trial.

Adjuvant therapy with sunitinib after nephrectomy was associated with increased mortality among older women with renal cell carcinoma, according to a subgroup analysis of data from the ASSURE trial.

Combining axitinib and pembrolizumab is “safe and tolerable” among patients with previously untreated advanced renal cell carcinoma, with 73% of patients responding, according to findings from an open-label, phase Ib trial.